- Fresenius Mabxience announces a CDMO agreement with Biosidus.
- The collaboration aims to develop a treatment for Fabry disease.
- This partnership represents a significant step in the fight against this rare genetic disorder.
Fresenius Mabxience has announced a Contract Development and Manufacturing Organisation (CDMO) agreement with Biosidus. This collaboration aims to develop a treatment for Fabry disease, a rare genetic disorder.
The use of Agalsidase Beta is an innovative treatment for Fabry disease. This disease arises from the complete or partial deficiency of the lysosomal enzyme a-galactosidase A, which leads to a pathological accumulation of glycosphingolipids in vascular walls, differentiated cells and fluids. Recent analysis of some international research on newborns shows an incidence of 1 in 22,570 men with classic forms and 1 in 1,390 with late forms, making it the most common lysosomal deposition disease.
“This agreement with Biosidus not only reflects our technical expertise and experience in CDMO and producing biopharmaceuticals, but also our commitment to improving global health through the provision of accessible and effective medicines,” said Jurgen Van Broeck, Global Commercial Director of mAbxience. “We are proud to collaborate in the manufacture of Biosidus’ Agalsidase Beta, a crucial product for those patients diagnosed with Fabry disease.”
Mariano de Elizalde, CEO of Biosidus said: “The alliance with mAbxience represents an important step in our mission to lead in the field of biotechnology in emerging markets. This agreement allows us not only to expand our product portfolio but also to bring innovative therapeutic solutions, developed with international standards of excellence and accessible in price for health systems, in the field of rare diseases.”
The agreement highlights both companies’ vision to lead the biopharmaceutical industry by combining mAbxience’s technical expertise and manufacturing capabilities with Biosidus’ innovation and patient focus. This joint effort is expected to have a significant impact on the lives of patients affected by Fabry disease by providing access to essential treatments in Argentina and subsequently in other countries around the world.
Overview of outsourcing trends 
